WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that the company will present at two meetings in December:
- 31st Annual Piper Jaffray Healthcare Conference, Thursday, Dec. 5, 2019 at 8:10 a.m. EST in New York, NY.
- FORMA Investor Lunch at the 2019 ASH Annual Meeting, Monday, Dec. 9, 2019 at 12:00 p.m. EST at the Hilton Orlando. Presentations will highlight FT-4202, a novel, selective pyruvate kinase-R (PKR) activator in sickle cell disease, and olutasidenib, an IDH1m inhibitor that acts as a single agent or in combination with azacitidine in acute myeloid leukemia (AML) and myelodysplastic syndrome. This event will be webcast and can be accessed through FORMA Therapeutics Investor page. A replay of the webcast will be available approximately two hours after the completion of the live event.
About FORMA
FORMA Therapeutics is focused on the discovery, development and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. A fully-integrated biopharmaceutical company, FORMA’s validated, proprietary R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create differentiated drug candidates with best-in-class or first-in-class potential. FORMA has delivered high-value clinical candidates to its partners and generated a broad proprietary portfolio of programs, ranging from preclinical to pivotal-stage, with the potential to provide profound patient benefit. For more information, please visit the company website at www.formatherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
